Research of dabigatran in children with thromboembolic diseases
In recent years,the incidence of venous thromboembolism in children is gradually increasing.As a new type of direct oral anticoagulant,dabigatran has the advantages of fixed dose,convenient oral administration,no need to monitor international standardized ratio,few interactions with food and drugs,fast onset,and short plasma half-life.Dabigatran has therefore become an important drug for the prevention and treatment of thromboembolism in children.Dabigatran etexilate oral granules were approved by the FDA in June 2021 for venous thrombosis and recurrent thrombosis in children aged 3 months to 12 years old.At the same time,dabigatran etexilate oral capsules were approved for the treatment of venous thrombosis in children aged 8 years and above,as well as for preventing the recurrence of thrombosis after the first venous thrombosis treatment.This article reviewed the research progress of dabigatran in the prevention and treatment of thromboembolic diseases in children.
NETL
NSTL
万方数据
